SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test whether SU011248 has activity and is safe compared to
interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (RCC).